Infinity Pharmaceuticals traded at $1.15 this Friday August 12th, increasing $0.07 or 6.48 percent since the previous trading session. Looking back, over the last four weeks, Infinity Pharmaceuticals gained 75.57 percent. Over the last 12 months, its price fell by 62.90 percent. Looking ahead, we forecast Infinity Pharmaceuticals to be priced at 0.78 by the end of this quarter and at 0.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.15
Daily Change
6.48%
Yearly
-62.90%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,115.00 20.00 0.33% -33.38%
AbbVie 142.60 0.52 0.37% 22.42%
Amgen 248.39 0.04 0.02% 8.15%
AstraZeneca 10,712.00 206.00 1.96% 27.13%
Bristol-Myers Squibb 75.57 1.11 1.49% 11.94%
Plus Therapeutics, Inc. 0.53 0.003 0.61% -74.61%
Gilead Sciences 62.96 0.51 0.82% -11.52%
Genocea Biosciences 0.01 0 0% -99.39%
GlaxoSmithKline 1,450.00 50.00 3.57% -2.80%
Incyte Corp 73.99 0.23 0.31% 0.71%
Infinity Pharmaceuticals 1.15 0.07 6.48% -62.90%
Ionis Pharmaceuticals 44.10 0.66 1.52% 11.14%
J&J 165.30 -1.84 -1.10% -6.21%
Eli Lilly 308.08 6.91 2.29% 16.60%
Mirati Therapeutics 86.37 5.92 7.36% -38.38%
Novartis 80.10 -0.94 -1.16% -6.82%
Pfizer 50.11 1.82 3.77% 3.36%
Roche Holding 315.00 4.85 1.56% -14.39%
Seattle Genetics 170.14 -3.90 -2.24% 8.76%
TG Therapeutics 8.31 0.79 10.51% -63.54%
Vascular Biogenics 0.24 -0.01 -4.04% -89.33%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., incorporated on May 11, 2000, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for people with cancer. It is also focusing on advancing, eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its pipeline includes MARIO-275 is, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line setting for triple negative breast cancer (TNBC), and front-line renal cell carcinoma (RCC). MARIO-1 is in Phase I /1b clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity for eganelisib.